Neway Valve (603699.SH) plans to invest approximately 500 million yuan to implement the second phase expansion project of Neway Fluid, expanding production capacity.
Neway Valve (Suzhou) Co., Ltd., a subsidiary of Neway Valve (603699.SH), announced...
Neway Valve (603699.SH) announced that its subsidiary Neway Fluid Control (Suzhou) Co., Ltd. (referred to as "Neway Fluid") plans to carry out the "Neway Fluid Phase II Expansion Project," with an estimated investment amount of about 500 million yuan, and is expected to be completed and put into operation by June 2027.
The project plans to build approximately 20,000 square meters of production plants and supporting facilities, as well as to expand more than 2 industrial valve production lines. The project site is located north of the Neway Fluid Phase I and east of the China Automotive Engineering Research Institute, with a land area of approximately 48.72 mu, for the construction of production plants and corresponding supporting facilities.
The announcement stated that if this investment can proceed smoothly, it will help further expand the company's industrial valve production capacity to meet the needs of the company's future market expansion and business development.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025